NASDAQ:BEAM

Beam Therapeutics Stock Forecast, Price & News

$85.00
0.00 (0.00 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$82.62
$85.99
50-Day Range
$64.12
$91.96
52-Week Range
$18.76
$126.90
Volume854,618 shs
Average Volume965,192 shs
Market Capitalization$5.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.01
30 days | 90 days | 365 days | Advanced Chart
Receive BEAM News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Beam Therapeutics logo

About Beam Therapeutics

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.27 out of 5 stars

Medical Sector

901st out of 2,100 stocks

Biological Products, Except Diagnostic Industry

131st out of 198 stocks

Analyst Opinion: 2.3Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Beam Therapeutics (NASDAQ:BEAM) Frequently Asked Questions

Is Beam Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Beam Therapeutics stock.
View analyst ratings for Beam Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Beam Therapeutics?

Wall Street analysts have given Beam Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Beam Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Beam Therapeutics' next earnings date?

Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Beam Therapeutics
.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) issued its quarterly earnings data on Monday, May, 10th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $2.61. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $6 million. Beam Therapeutics had a negative net margin of 1,523,724.75% and a negative trailing twelve-month return on equity of 113.20%.
View Beam Therapeutics' earnings history
.

How has Beam Therapeutics' stock price been impacted by Coronavirus?

Beam Therapeutics' stock was trading at $21.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BEAM stock has increased by 300.0% and is now trading at $85.00.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BEAM?

8 Wall Street analysts have issued 1-year target prices for Beam Therapeutics' shares. Their forecasts range from $33.00 to $145.00. On average, they expect Beam Therapeutics' share price to reach $94.17 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price.
View analysts' price targets for Beam Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Beam Therapeutics' key executives?

Beam Therapeutics' management team includes the following people:
  • Mr. John M. Evans M.B.A., CEO & Director (Age 43, Pay $906.77k)
  • Dr. Giuseppe Ciaramella, Pres & Chief Scientific Officer (Age 52, Pay $746.24k)
  • Ms. Terry-Ann Burrell M.B.A., CFO & Treasurer (Age 44, Pay $683.75k)
  • Dr. Feng Zhang, Co-Founder
  • Dr. David R. Liu, Co-Founder
  • Dr. J. Keith Joung, Co-Founder
  • Mr. Brian Riley, Sr. VP of Technical Operations (Age 44)
  • Dr. Christine P. Bellon, Sr. VP, Chief Legal Officer & Corp. Sec. (Age 55)
  • Ms. Susan O'Connor, Chief HR Officer (Age 57)
  • Ms. Courtney Wallace, Chief Bus. Officer (Age 37)

What is 's approval rating as Beam Therapeutics' CEO?

1 employees have rated Beam Therapeutics CEO on Glassdoor.com. has an approval rating of 100% among Beam Therapeutics' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Beam Therapeutics' key competitors?

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Square (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Beam Therapeutics' stock symbol?

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (7.64%), BlackRock Inc. (4.94%), Redmile Group LLC (4.05%), MWG Management Limited (3.78%), Hillhouse Capital Advisors LTD. (3.31%) and Goldman Sachs Group Inc. (1.17%).
View institutional ownership trends for Beam Therapeutics
.

Which institutional investors are selling Beam Therapeutics stock?

BEAM stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Hillhouse Capital Advisors LTD., Cormorant Asset Management LP, Goldman Sachs Group Inc., Lord Abbett & CO. LLC, Ensign Peak Advisors Inc, BlackRock Inc., and Federated Hermes Inc..
View insider buying and selling activity for Beam Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Beam Therapeutics stock?

BEAM stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, MWG Management Limited, Perceptive Advisors LLC, Victory Capital Management Inc., Monashee Investment Management LLC, University of Texas Texas AM Investment Managment Co., Bellevue Group AG, and Morgan Stanley.
View insider buying and selling activity for Beam Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Beam Therapeutics?

Shares of BEAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Beam Therapeutics' stock price today?

One share of BEAM stock can currently be purchased for approximately $85.00.

How much money does Beam Therapeutics make?

Beam Therapeutics has a market capitalization of $5.32 billion and generates $20,000.00 in revenue each year. The company earns $-194,590,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

How many employees does Beam Therapeutics have?

Beam Therapeutics employs 216 workers across the globe.

What is Beam Therapeutics' official website?

The official website for Beam Therapeutics is www.beamtx.com.

Where are Beam Therapeutics' headquarters?

Beam Therapeutics is headquartered at 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139.

How can I contact Beam Therapeutics?

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-327-8775 or via email at [email protected]


This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.